BONESUPPORT HOLDING AB NPV revenue breakdown overview

BONESUPPORT HOLDING AB NPV revenue for the last year amounted to 591.00 M SEK, the most of which — 358.24 M SEK — came from its highest performing source at the moment, Cerament Gentamicin and Ceramanent Vancomycin, the year earlier bringing 112.17 M SEK. The greatest contribution to the revenue figure was made by North America — last year it brought BONESUPPORT HOLDING AB NPV 442.45 M SEK, and the year before that — 216.88 M SEK.